Expanded Access to Gallium Maltolate (GaM)

Part of paid clinical trials in Miami, Florida.

Sponsor
Imaging Biometrics, LLC
Study ID
NCT06404034
Status
Available

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Gallium Maltolate — DRUG
    GaM will be provided as 500 mg capsules and will be self-administered once daily by mouth at the assigned dose level on a 28-day cycle (one cycle is 28 days) on an empty stomach. GaM should be taken at least 60 minutes before a meal and at least two hours after a meal. Liquids are allowed

Study Details

The objective of this program is to provide GaM for compassionate use in patients with relapsed/refractory histologic or molecular glioblastoma who have exhausted available treatments. The population of this program is adult patients aged greater than or equal to 18 years with a diagnosis of relapsed/refractory histologic or molecular glioblastoma, according to the WHO 2021 diagnostic criteria. Molecular glioblastoma is characterized as an IDH-wildtype diffuse and astrocytic glioma in adults if there is microvascular proliferation or necrosis or TERT promoter mutation or EGFR gene amplification or +7/-10 chromosome copy number changes

Key Dates

Status verified
Jun 2026

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
University of Miami Sylvester Comprehensive Cancer CenterMiamiFlorida33136
Dr. Macarena De La Fuente, MD
305-243-0864
Cancer Partners of NebraskaLincolnNebraska68516
Brett Greib, MD
Northwell HealthNew YorkNew York10075
Tamika A. Wong, MPH
212-434-4836
Dr. John Boockvar, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Miami, FL

By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
University of Miami Sylvester Comprehensive Cancer Center· Miami, FLCancer Partners of Nebraska· Lincoln, NENorthwell Health· New York, NY

Related Studies